-
Mashup Score: 38Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk - 5 month(s) ago
This comparative effectiveness study, a prespecified analysis from the MASTER DAPT trial, reports sex differences and the association of sex with outcomes among patients with high bleeding risk treated with an abbreviated vs standard dual antiplatelet therapy regimen.
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 11Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk: - 2 year(s) ago
Abstract Background The optimal duration of antiplatelet therapy (APT) after coronary stenting in patients at high bleeding risk (HBR) presenting with an acute coronary syndrome remains unclear. Ob…
Categories: Expert Picks, Latest HeadlinesTweet-
One-month dual antiplatelet therapy vs ≥3 months dual antiplatelet therapy in #HighBleedingRisk patients did not differ in ischemic risk but lowered bleeding risk: https://t.co/EK29mgpa6M #JACC #MasterDAPT #cvMI #cvACS #CardioTwitter @FelixMahfoud @GoranEBC @vlgmrc https://t.co/7I7CvktNMC
-
-
Mashup Score: 10Beyond the Data: Abbreviated DAPT After Complex PCI in High-Bleeding-Risk Patients - tctmd.com - 2 year(s) ago
Specialty Menu Navigation COVID-19 Clinical Coronary Structural Endovascular …
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
#EuroPCR my interview with @vlgmrc discussing #MASTERDAPT and complex PCI in HBR ➡️https://t.co/lAsF3hPrVK @TCTMD story here ➡️https://t.co/ccLsRH8o48 @aayshacader @ncurzen @sbrugaletta @Costa_F_8 @WijnsWilliam @alaide_chief @Hragy @LAzzaliniMD @VijayKunadian @twj1974 @ShrillaB https://t.co/eGG5wDxTwZ
-
Beyond the Data: Abbreviated #DAPT After Complex PCI in High-Bleeding-Risk Patients #EruoPCR Prof.@mmamas1973 hears from Prof.Marco Valgimigli about this key subgroup analysis from MASTER DAPT @TCTMD @TCTMD_Yael @ShelleyZieroth @PCRonline @EAPCIPresident https://t.co/LCsGfitesG https://t.co/jAInRzbZeh
-
-
Mashup Score: 3
AbstractAims. To assess the effects of 1- or ≥3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients who received biodegradable-polymer s
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Duration of Antiplatelet Therapy After Complex Percutaneous Coronary Intervention In Patients at High Bleeding Risk: a MASTER DAPT trial sub-analysis presented at #EuroPCR2022! https://t.co/NmIcRQ2kU7 #DAPT #MASTERDAPT #bleeding #PCI #cardiotwitter @escardio @ESC_Journals https://t.co/uYuxlEHXyg
-
-
Mashup Score: 1TCT 2021 - 2 year(s) ago
Educational Grant SupportTCT is sponsored by the Cardiovascular Research Foundation (CRF) and partially funded through educational grants from commercial supporters.This program is made possible in part by the educational grant support of our industry colleagues who, like CRF, are dedicated to educating medical professionals and the public to enhance patient outcomes. CRF gratefully acknowledges…
Source: tct2021.crfconnect.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Check out today's late-breaking data in the Clinical Science Theater at #TCT2021! Session begins at 1:00 PM ET featuring presentations of #AMULETIDE #PRAGUE17 #MASTERDAPT #STOPDAPT2 @DJ_Lakkireddy @POsmancik @KoYamamoto7 @ehj_ed https://t.co/oi01W0M6FE https://t.co/VPrxzWoekY
-
-
Mashup Score: 1
Researchers have found that for high bleeding risk individuals, one month of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with biodegradable-polymer sirolimus-eluting stents reduces bleeding risk and is non-inferior for adverse clinical and cardiac/cerebral events as compared to three months or more of DAPT.
Source: Docwire NewsCategories: Cardiologists, Latest HeadlinesTweet-
New article with @CardioNerds summarizing #MASTERDAPT on weighing ⚖️the dueling ⚔️risks and benefits of DAPT post-PCI in patients with high bleeding risk 🩸🩸🩸 Check it out here: https://t.co/z8p3T2b7Pv
-
-
Mashup Score: 1
Background: The optimal duration of antiplatelet therapy (APT) in patients at high bleeding risk with or without oral anticoagulation (OAC) after coronary stenting remains unclear. Methods: In the in
Source: CirculationCategories: Cardiac Surgery, Latest HeadlinesTweet-
#OriginalResearch simpub with #ESCCongress: #MASTERDAPT sub-study, 1 month of DAPT compared to >3 months in high bleeding risk patients did not increase ischemic risk but lowered bleeding risk in patients w/o OAC indication https://t.co/XU9fLLgYym #CircESC2021 #AHAJournals https://t.co/2vL2WX2ADG
-
-
Mashup Score: 1
Original Article from The New England Journal of Medicine — Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
Source: New England Journal of MedicineCategories: Cardiology News and Journals, Latest HeadlinesTweet-
RT @hect2701: #ESCCongress #MASTERDAPT interview https://t.co/1J7DtGtYtK @CiticMexico @SOCiME_ @PCRonline @TCTMD @CRT_meeting https://t.c…
-
-
Mashup Score: 8MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients - 3 year(s) ago
#ESCCongress 2021: Luis G. Ortega-Paz interviews Marco Valgimigli about the MASTER-DAPT trial to assess whether one month of dual antiplatelet therapy preser…
Source: YouTubeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Here it is! @Ortega_Paz interviews 🎤@vlgmrc co-PI of the #MASTERDAPT trial as he covers points like precise-DAPT for patient selection, LT treatment in HBR patients, future perspectives in HBR and #DAPT & more. 📺https://t.co/AxIQmCp55W #ESCCongress https://t.co/1CWi0NPCZU
-
-
Mashup Score: 9
(UPDATED) In an all-comers HBR group, 1-month DAPT was noninferior to 3 months or longer, at least with the bioresorbable stent used here.
Source: TCTMD.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
RT @mmamas1973: #ESCCongress @TCTMD @ShelleyWood2 coverage of #masterdapt https://t.co/ckDObFsqcs can we apply the results of the study to…
-
Abbreviated or Standard DAPT by Sex in Patients at HBR A Prespecified Secondary Analysis of #MASTERDAPT Our work published @JAMACardio 🔗 https://t.co/MzVMpPi5wB @antoniolandii @vlgmrc @alaide_chief @DrLucaTesta et al 📮Ischemic & bleeding risks were comparable 📮There was… https://t.co/2N3unKcRzH https://t.co/ETQhBc362U